A A A

News & Medical Papers

 

For current guidelines and updates from within the arrhythmia healthcare community please visit Arrhythmia Watch.

Implantation of multiple leadless pacemakers is feasible without impacting cardiac function

Cardiac Rhythm News, 5 February 2016

An animal study from China has indicated that it is feasible to implant two leadless pacemakers in the right ventricle of the same heart without impacting cardiac function at six months.

Read more


Cardiologists expose concerns regarding battery life of cardiac implantable electronic devices

Cardiac Rhythm News, 4 February 2016

The battery life of cardiac implantable electronic devices must be improved to reduce the need for replacement and the risks this carries for patients, argue UK cardiologists John Dean and Neil Sulke in an editorial published in BMJ.

Read more


Vasovagal Syncope and Driving

American College of Cardiology, 4 February 2016

What is the likelihood of a motor vehicle accident causing serious risk or harm in patients with frequent vasovagal syncope?

Read more


NICE targets stroke with possible new indicators for GPs and clinical commissioners

NICE, 1 February 2016

NICE – the National Institute for Health and Care Excellence – is consulting on potential new indicators for the NICE indicator menu. Indicators encourage health professionals to assess patients on a range of key health issues where diagnosis and treatment is supported by evidence-based guidelines. The aim is to tackle widespread public health challenges one patient at a time.

Read more


Stroke prevention in atrial fibrillation: we can do better

British Journal of General Practice, 1 February 2016

Atrial fibrillation (AF), an irregular and often rapid cardiac rhythm, is the most common sustained cardiac dysrhythmia.

Read more


 

MRI safe for patients with implantable cardiac devices

News Medical, 30 January 2016

The findings of a major study led by cardiovascular imaging specialists at Allegheny General Hospital (AGH), part of the Allegheny Health Network (AHN), suggest that magnetic resonance imaging is a safe and effective diagnostic procedure for patients with implantable cardiac devices. The research, believed to be the first ever focused solely on the value of MRI in this patient population, is being presented today at the annual Society of Cardiovascular MRI Scientific Sessions meeting in Los Angeles.

Read more


 

Driving and Vasovagal Syncope? Serious Accidents, Harm Rare

Medscape, 28 January 2016

Researchers estimate that the incidence of driving and having a serious accident causing bodily injury or death is much lower in patients with frequent vasovagal syncope than in the general population (<0.0035% per person year vs 0.067% per driver-year)[1]. The study was published online January 20, 2016 in JACC: Clinical Electrophysiology.

Read more


No need to get up! Doctors can accurately measure subtle changes in your heartbeat from across the room without touching you

Mail Online, 20 January 2016

Scientists are working on a method of detecting your heartbeat without sensors on the body, which they claim is as accurate as an electrocardiogram (ECG).

Read more


AliveCor Partners with LifeWatch to Expand Into Remote Patient Monitoring

AliveCor, 12 January 2016

AliveCor, Inc., the leader in FDA-cleared ECG technology for mobile devices, announced today a strategic partnership with LifeWatch AG (SIX Swiss Exchange: LIFE), a leading developer of medical solutions and remote diagnostic monitoring services to the digital health market. The AliveCor Mobile ECG will now be integrated into LifeWatch’s remote cardiac monitoring service, AliveCor’s first step into remote patient monitoring.

Read more


Has leadless pacing changed practice?

Cardiac Rhythm News, 18 January 2016

Since the implantation of the first pacemaker in humans in 1958, pacing for bradycardia has not changed substantially. While the art is mature, pacing still involves a surgical procedure to create a pocket for the pacemaker, and venous access to introduce one or more pacing leads into the cardiac chamber(s).

Read more


Women and men with heart failure benefit similarly from implantable cardioverter defibrillators

Cardiac Rhythm News, 18 January 2016

An analysis from the US Get with the guidelines for heart failure (GWTG-HF) registry has found that women and men with heart failure and reduced left ventricular ejection fraction benefit similarly from implantable cardioverter defibrillators (ICDs).

Read more


World's smallest pacemaker on trial in Princess Alexandra Hospital

Brisbane Times, 15 January 2016

A Queensland hospital is leading the Australian-first trial of the world's smallest pacemaker, labelled the biggest game changer in six decades.

Read more


Implantable Defibrillators Effective for Women Too

Medpage Today, 12 January 2016

Implantable cardioverter defibrillators (ICDs) boost survival for women and men with heart failure alike -- even if the benefits of ICDs haven't been as well studied for women -- according to a registry study.

Read more


 Zoll LiveVest wearable defibrillator receives FDA approval for paediatric use

Cardiac Rhythm News, 18 December 2015

Zoll Medical’s LiveVest wearable cardioverter defibrillator has been approved for a new paediatric indication by the US Food and Drug Administration. It is now approved for use by certain children who are at risk for sudden cardiac arrest, but who are not candidates for an implantable defibrillator device due to certain medical conditions, or a lack of parental consent.

Read more


First patient enrolled in international CEASE atrial fibrillation study

Cardiac Rhythm News, 17 December 2015

The first patient has been enrolled in the CEASE (combined endoscopic epicardial and percutaneous) atrial fibrillation (AF) clinical study, according to a press release from AtriCure.

Read more


 

Advances in left atrial appendage occlusion and peri-procedural challenges

Cardiac Rhythm News, 17 December 2015

Dhiraj Gupta (Liverpool, UK) overviews developments in two left atrial appendage (LAA) occlusion devices, which have helped make the implant procedure safer, easier and quicker. He also highlights current challenges related to overall peri-procedural patient management.

Read more


Arrhythmia & Electrophysiology Review (AER)

Radcliffe Cardiology, 14 December 2015

Volume 4 Issue 3 Winter 2015

View the eJournal's here


 

US cardiovascular societies publish joint expert consensus on left atrial appendage occlusion requirements

Cardiac Rhythm News, 11 December 2015

The Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC) and the Heart Rhythm Society (HRS) have published a joint document providing recommendations—for institutions and interested physicians—for the establishment and maintenance of left atrial appendage occlusion programmes performing left atrial appendage closure.

Read more


CRT-D Longevity Comparison Post-2006

Boston Scientific, 10 December 2015

NEW: An 8th independent longevity study with 3,436 patients shows that 97.6% of modern Boston Scientific CRT-Ds survive at 6 years, compared to only 46.3% of modern Medtronic CRT-Ds, once again showing that Boston Scientific CRT-Ds have significantly better survival than Medtronic CRT-Ds at 6-years post-implant1.

View more here


GPs face drive to prescribe warfarin alternatives under new NICE plans

Pulse Today, 10 December 2015

GPs face a drive to prescribe warfarin alternatives, as NICE has decided to consider new QOF indicators for anticoagulation control.

Read more


SUDEP May Share Genes With Sudden Cardiac Death

MedPage Today, 8 December 2015

Similar genes that are involved in cardiac arrhythmias may play a role in sudden unexplained death in epilepsy (SUDEP), researchers reported here.

Read more


Leicester City CCG shortlisted in Health Business Awards for its usage of INRstar analytics

SCSL Health, 7 December 2015

Leicester City CCG has been shortlisted within the Healthcare IT category of this year’s Health Business Awards for its usage of INRstar analytics.

Read more


Medtronic recalls InSync III pacemakers due to battery issue
03 December 2015

Medtronic confirms it has informed physicians and regulatory authorities of an issue with the long-term battery performance of its InSync® III cardiac resynchronization therapy-pacemakers (CRT-Ps).

It is important to note that the InSync III CRT devices are an older set of devices no longer being distributed. The company has confirmed 0.03 percent of implanted InSync III devices have been affected.
Patients who have this device and who have concerns or who experience new or unexpected symptoms associated with their heart condition should seek guidance from their physicians.


Boehringer Ingelheim's Praxbind gets European approval for specific reversal of Pradaxa

Pharmabiz, 28 November 2015

The European Commission has approved Boehringer Ingelheim's Praxbind (idarucizumab), a treatment to rapidly and specifically reverse the anticoagulant effects of Pradaxa (dabigatran etexilate) in cases of emergency surgery /urgent procedures or in situations of life-threatening or uncontrolled bleeding. Idarucizumab is the first specific reversal agent for a non-vitamin K antagonist oral anticoagulant (NOAC) to be approved in the European Union.

Read more


Atrial Fibrillation Stroke: SCSLhealth release new, Commissioner Guide on how to improve population coverage of anticoagulation for commissioners

SCSL Health, 25 November 2015

SCSLhealth – provider of the UK’s market leading software for AC management (INRstar) has announced the release of a new document to help Clinical Commissioning Groups (CCGs), Commissioning Support Units (CSUs) and Local Health Boards (LHBs) to improve population coverage of anticoagulation by outlining a suite of recommendations, tools and resources to support implementation of NICE Clinical Guidelines on the management of Atrial Fibrillation.

Read the full press release here
Download you FREE copy of the AF stroke report here


S-ICD System 2-Year Results - Pooled Analysis of the IDE Study and EFFORTLESS Registry

Boston Scientific, 24 November 2015

Watch the conclusions of the largest and most comprehensive S-ICD data set, with the longest follow-up to date here


Asymptomatic Atrial Fibrillation
The Case for Screening to Prevent Stroke

American Medical Association, 10 November 2015

Could unknown asymptomatic atrial fibrillation be detected easily as a way to prevent stroke?

Read more


 

Are energy drinks safe enough for the heart?

Cardiac News, 5 November 2015

Despite the lack of randomised trials on energy drinks consumption, few case reports on atrial and ventricular arrhythmias as well as on myocardial ischaemia inducted by energy drinks have raised concerns on the safety of these beverages.

Read more


 

World Stroke Day: Key Risk Factors Atrial Fibrillation and Hypertension Need Detection and Treatment

Pharmiweb, 28 October 2015

On World Stroke Day (29 October) a campaign by Daiichi Sankyo highlights stroke risks associated with cardiovascular diseases

Read more


Blackouts and near drownings may signal sudden death risk

Cardiac Rhythm News, 26 October 2015

Blackouts and near drownings may point to long QT syndrome (LQTS), signalling an increased risk of sudden death, according to research presented at the SA Heart Congress (25-28 October, Sun City, South Africa) by Paul Brink, professor of internal medicine at the University of Stellenbosch in Tygerberg, South Africa.

Read more


Dabigatran Reversal Drug Holds Promise

Medpage Today, 17 October 2015

Preliminary research suggests idarucizumab can reverse anticoagulant's bleeding risk

Read more


FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

FDA, 16 October 2015

The U.S. Food and Drug Administration today granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa’s blood-thinning effects. 

Read more

Read Boehringer Ingelheim Press Release


AF Atrial Fibrillation Symposium

NWC AHSN, 26 June 2015

The North West Coast Academic Health Science Network is celebrating a successful event which looked at innovative new ways to tackle and manage Atrial Fibrillation (AF) - which causes irregular heartbeats and is a major cause of strokes.

Read more


CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)

Boehringer Ingelheim, 28 September 2015

Today, the Committee for Medicinal Products for Human use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending European approval of idarucizumab (to be marketed as Praxbind®).

Read more


European Medicines Agency recommends dabigatran antidote after accelerated assessment

Cardiac Rhythm News, 25 September 2015

The European Medicines Agency (EMA) has recommended granting a marketing authorisation, following accelerated assessment, for idarucizumab (Praxbind, Boehringer Ingelheim) as a specific antidote to dabigatran etexilate (Pradaxa, Boehringer Ingelheim) when rapid reversal of its effect is required. Idarucizumab is to be used when a patient taking dabigatran needs to undergo an emergency surgery or when life-threatening or uncontrolled bleeding occurs.

Read more


NICE approves new oral anti-coagulant for atrial fibrillation

Nursing Times, 24 September 2015

The drug edoxaban has been given the official seal of approval for NHS use in preventing stroke and blood clots in patients with a common heart disorder.

Read more


The Beauty of Subcutaneous ICDs Is Not Merely Skin Deep

Cardiovascular Business, 23 September 2015

Three decades and 1 million-plus implantations after its introduction, the transvenous implantable cardioverter-defibrillator (T-ICD) is facing stiff competition from a smaller, thinner, more versatile and longer lasting addition to the family tree of implantable devices that shock the heart to prevent sudden cardiac death.

Read more


Cohorts, Meta-Analysis: No Link Between Coffee and Increased Risk for Atrial Fibrillation

Medspace, 23 September 2015

More research is weighing in with a resounding "no" on whether downing coffee may be detrimental to cardiovascular health in otherwise-healthy adults.

Read more


Matters of the heartbeat: Electric irregularity a danger for many

tdtnews, 23 September 2015

Dr. Javier E. Banchs, cardiologist Baylor Scott & White — Central Division, director of electrophysiology and pacing, spoke about the medical problem at the Belton Senior Expo on Tuesday.

Read more


SJM™ Quadra CRT System

St. Jude Medical, 22 September 2015

The SJM™ Quadra family of devices, with the Quartet™ LV lead, set the standard for quadripolar technology. With 10+ years of design experience, 100+ publications and 100,000+ implants, the SJM Quadra CRT system is pioneering outcomes with proven performance and unmatched data.
The SJM Quadra CRT system is part of the comprehensive heart failure portfolio from St. Jude Medical.

Read more


Battery depletion in CRT Defibrillators by vendor

Boston Scientific, 22 September 2015

Dr. Ernest Lau's recent independent study showed a clinically meaningful difference in CRT-D longevity by manufacturer at six years.*

Read more


Recent ESC Guidelines to Identify Hypertrophic Cardiomyopathy Patients at High Risk for Sudden Death Are Unreliable

Alpha Galileo, 21 September 2015

Hypertrophic cardiomyopathy (HCM), a genetic form of heart disease with thick heart walls, is the most common cause of sudden death in patients under 50. While only a minority of patients with HCM are at risk, the implantable cardioverter-defibrillator (ICD) can effectively prevent sudden death in those patients.

Read more


FIRST LOOK: Huntsville Hospital expands electrophysiology services

Tech Alabama, 18 September 2015

Huntsville Hospital is giving Tech Alabama a first look at its newest electrophysiology lab.

Read more


 Laguna Pharmaceuticals initiates phase 3 study of vanoxerine in atrial fibrillation and atrial flutter -

Cardiac Rhythm News, 17 September 2015

The study, known as RESTORE SR, will enrol 600 patients at trial sites in the USA and other countries and will evaluate vanoxerine at a 400mg dose. In the phase 2b COR-ART study, this dose was effective in restoring sinus rhythm in greater than 80% of patients, a level approaching that of the leading intervention—delivery of electrical shock to the heart with direct current cardioversion.

Read more


Catheter Ablation Superior to Drug Therapy for Atrial Fibrillation

HospiMedica, 17 September 2015

A new study concludes that first-line treatment with radiofrequency ablation (RFA) is superior to antiarrhythmic drug therapy (AAD) for reducing atrial fibrillation (AF).

Read more


Medtronic Wins FDA Clearance For First MRI-Safe ICD

Med Device Online, 16 September 2015

Medtronic announced that it has gained U.S. Food and Drug Administration (FDA) approval for the first-ever implantable cardioverter defibrillator (ICD) device that can be safely used by patients undergoing full-body magnetic resonance imaging (MRI) scans.

Read more


Health Report: Alternatives to drugs offer new ways to treat Atrial Fibrillation

KUSI News, 16 September 2015

According to the National Institute of Health, most adults have an average heart rate of 60 to 100 beats per minute. Most of the time, you don’t think about how fast your heart is beating unless you’re exercising, feeling stressed -- or have cardiac arrhythmia.

Read more


Area doctors keep an eye on the heart's electrical system

Portland Tribune, 15 September 2015

Electrophysiology is one of the fasted growing fields in cardiac care, and at Northwest Regional Heart and Vascular (Adventist Medical Center in Portland), Dr. Fawaz Alhumaid and colleagues are hard at work analyzing the heart’s rhythm and electrical conduction system.

Read more


CardioFocus' HeartLight PMA for the treatment of atrial fibrillation filed and accepted for review by the FDA

Cardiac Rhythm News, 15 September 2015

CardioFocus’ Premarket Approval (PMA) application for its HeartLight device has been filed and accepted for review by the US Food and Drug Administration (FDA). The accepted PMA application includes safety and effectiveness data from the company’s multicentre HeartLight pivotal clinical trial, a randomised, controlled study in which a total of 353 patients were treated at 19 leading arrhythmia centres across the USA.

Read more


LEADLESS II shows positive safety and efficacy outcomes with Nanostim

Cardiac Rhythm News, 15 September 2015

Primary results from the LEADLESS II study have shown positive efficacy and safety outcomes with the Nanostim leadless pacemaker (St Jude Medical) for patients who require a single-chamber ventricular pacemaker.

Read more


An aspirin a day DOES help prevent heart attack, stroke and colon cancer - but it's most effective if you're in your 50s

Daily Mail, 14 September 2015

A daily low dose of aspirin should be given to people in their 50s to prevent a heart attack or stroke, new guidelines recommend.

Read more


3D imaging of kids' hearts

News4Jax, 14 September 2015

More than 4 million Americans are living with heart arrythmias meaning they have hearts that don't always beat in a steady rhythm.

Read more


Apixaban Cost-Effective in Afib Patients With Low Stroke Risk

Medpage Today, 14 September 2015

Treatment with apixaban (Eliquis) versus aspirin was associated with fewer strokes but more bleeding episodes in nonvalvular atrial fibrillation patients with a low risk for stroke in the first study to compare the cost-effectiveness of a non-VKA oral anticoagulant (NOAC) with aspirin in this population.

Read more


First MRI-conditional implantable cardioverter defibrillator system receives FDA approval

Cardiac Rhythm News, 14 September 2015

Medtronic has announced that it has received the first US Food and Drug Administration (FDA) approval for an implantable cardioverter defibrillator (ICD) system for use with magnetic resonance imaging (MRI) scans.

Read more


Stroke Rounds: Anticoagulation After Afib Ablation

Medpage Today, 10 September 2015

Atrial fibrillation ablation quells symptoms and has other benefits, but is stroke prevention one of them?

Read more


Procedure Does Not Reduce Stroke Risk in Patients with Atrial Fibrillation

HCP Live, 9 September 2015

Left atrial appendage obliteration reduces stroke risk in patients with nonvalvular atrial fibrillation (AF), but a new study suggests that the procedure does not reduce stroke risk in AF patients after bioprosthetic mitral valve replacement.

Read more


Electrical left atrial appendage isolation helps to improve freedom from long-standing persistent AF

Cardiac Rhythm News, 7 September 2015

A randomised, multicentre study has found improvement in the long-term freedom from long-standing persistent atrial fibrillation (AF) in patients who underwent an ablation plus empirical electrical left atrial appendage isolation strategy. No major complications were reported.

Read more


ESC: Declining Renal Function May Be Bad News in Afib

MedPage Today, 3 September 2015

Patients with atrial fibrillation who also had declining renal function based on estimated glomerular filtration rates (eGFR) were significantly more likely to experience cardiovascular events, researchers reported here.

Read more


Stroke Rounds: Seizures More Common in Afib

MedPage Today, 3 September 2015

New-onset seizures are more common in atrial fibrillation, possibly linked by silent strokes, an observational study suggested.

Read more


ESC: Warfarin May Lower Dementia Risk in Afib Patients

MedPage Today, 3 September 2015

Patients with incident atrial fibrillation who were treated with warfarin to reduce the risk of strokes may also have had less chance of developing dementia, researchers suggested here.

Read more


Clinical trials launching to test iRhythm Zio Patch for atrial fibrillation screening in nearly 3,000 patients

MedPage Today, 3 September 2015

Two major studies are set to launch in the United States and Canada evaluating the use of the Zio Patch, a wearable ECG monitor, to screen for silent atrial fibrillation.

Read more


ESC recommends subcutaneous defibrillators for management of ventricular arrhythmias and prevention of sudden cardiac death

Cardiac Rhythm News, 2 September 2015

Updated ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death have been announced during the ESC Congress 2015 (29 August–2 September, London, UK).

Read more


Ready for Rio, but sports screening still controversial

European Society of Cardiology, 2 September 2015

The most common cause is an underlying genetic condition such as hypertrophic cardiomyopathy. However, as was made clear in a Young Investigators Award study on Sunday, many SCDs in sport may be associated with a structurally normal heart at postmortem examination - and are referred to at autopsy as ‘unexplained’.

Read more


ESC: Bleeding Risks Low in 'Real World' Rivaroxaban Patients

Medpage Today, 2 September 2015

A required post-marketing study indicates that the anticoagulant rivaroxaban (Xarelto) used for stroke prevention in patients with atrial fibrillation may have less bleeding safety issues than were seen in the drug's pivotal trial, researchers suggested here.

Read more


Increase in AED number prompts improved survival

European Society of Cardiology, 2 September 2015

A Danish study has found that the survival of cardiac arrest patients following bystander CPR increased from below 10% in 2001 to around 55%in 2012.

Read more


AF patients treated with rivaroxaban for stroke prevention experience low rates of bleeding and stroke

News Medical, 2 September 2015

Atrial fibrillation (AF) patients treated with rivaroxaban for stroke prevention have low rates of bleeding and stroke, reveals real-world data from the XANTUS study presented at ESC Congress today.

Read more


New studies identify gene associated with sudden cardiac death

Cardiac Rhythm News, 1 September 2015

First-of-its-kind findings from two independent studies have identified a gene associated with sudden cardiac death.

Read more


ESC: Non-Major Bleeding Less Frequent With Apixaban

Medpage Today, 1 September 2015

Non-major clinically relevant bleeding events occur more frequently with warfarin than with apixaban (Eliquis) in the ARISTOTLE trial, and carry an increased mortality risk to patients being treated with anticoagulants to prevent strokes caused by atrial fibrillation, researchers reported here.

Read more


Diploma in Syncope and related disorders

Royal College of Physicians of Ireland, 1 September 2015

After the success of our inaugural Diploma in Syncope and Related Disorder last year, we are happy to host this programme for 2015-2016.

Read more


New ESC Guidelines published on the management of ventricular arrhythmias and prevention of sudden cardiac death

European Society of Cardiology, 31 August 2015

The new ESC Guidelines for the management of patients with ventricular arrhythmias (VA) and the prevention of sudden cardiac death (SCD), written by 18 Task Force members and supported by 810 references, are very broad and comprehensive. The document had 74 peer reviewers, and it was our privilege to act as review coordinators.

Read more


Medtronic says trials find gene linked to sudden cardiac death

Yahoo News, 31 August 2015

Two studies have identified a gene associated with potentially fatal abnormal heart rhythms, device maker Medtronic Plc said on Monday.

Read more


Study shows AED usage has increased in public locations, but not at homes

News Medical, 31 August 2015

Efforts to improve automated external defibrillator (AED) usage increase bystander defibrillation in public places but not at home, reveals a study of more than 25 000 cardiac arrest patients presented at ESC Congress today by Dr Steen Hansen, a PhD student in the Department of Health, Science and Technology at Aalborg University in Denmark. Efforts included increased numbers of AEDs, cardiopulmonary resuscitation (CPR) education and a nationwide AED registry.

Read more


Persistent AF improved by isolation of left atrial appendage

European Society of Cardiology, 31 August 2015

In patients with long-standing persistent atrial fibrillation additional electrical isolation of the left atrial appendage (LAA) improved freedom from AF without increasing complications, reported the BELIEF study in the Hot Line session yesterday.

Read more


 Even watching the World Cup has heart risks

European Society of Cardiology, 31 August 2015

During the last three FIFA World Cups football fans experienced abrupt increases in heart rate comparable to that achieved during maximal treadmill exercise testing. Such heart rate changes, suggest French investigators, could be sufficient to increase the risk of cardiovascular events in vulnerable spectators.

Read more


No effect of ATP on late AF recurrence

European Society of Cardiology, 31 August 2015

Although radiofrequency catheter ablation has been developed as a curative therapy for AF, recurrent atrial tachyarrhythmias are estimated to occur in 30-40% of patients with paroxysmal AF, and 50-70% with persistent or long-lasting AF.

Read more


DISCOVERY/OREGON SUDS: Polymorphism in the GNAS Gene Predicts Ventricular Tachyarrhythmias and SCD

American College of Cardiology, 31 August 2015

A gene associated with sudden cardiac death in the general population has been identified using implantable cardioverter defibrillator (ICD) monitoring, and may predict ventricular tachyarrhythmias and sudden cardiac death, according to results from the DISCOVERY trial and Oregon Sudden Death Study presented Aug. 31 during ESC Congress 2015 in London.

Read more


Manage AFib Risk for Better Health

Wayne County Journal Banner, 31 August 2015

Approximately 1.5 million American women live with atrial fibrillation, a heart disorder commonly known as “AFib” that can lead to deadly or life-impairing stroke.

Read more


ESC guideline adherent antithrombotic management improves outcomes in AF patients

News Medical, 31 August 2015

Patients with atrial fibrillation who receive antithrombotic management according to ESC guidelines have better outcomes than those who do not, according to one year follow up results from the ESC's EORP-AF Pilot General Registry presented today at ESC Congress 20151 and published online in Europace.

Read more


BELIEF: Isolating Left Atrial Appendage May Halt Persistent AF

Medscape, 31 August 2015

In patients with persistent, recurrent atrial fibrillation (AF), performing electrical isolation of the left atrial appendage (LAA) as well standard catheter ablation and pulmonary-vein isolation may increase the chance of success, according to results from the BELIEF trial.

Read more


Multiple risk factors cancel impact of atrial fibrillation on ischaemic stroke risk

Health Canal, 31 August 2015

The impact of atrial fibrillation on ischaemic stroke risk in elderly patients is eliminated with multiple risk factors, according to an 11 year study in more than 425 000 patients presented at ESC Congress today.

Read more


Cold weather linked to increased stroke risk in atrial fibrillation patients

Medical Xpress, 30 August 2015

Cold weather is associated with increased risk of ischaemic stroke in patients with atrial fibrillation, according to research presented at ESC Congress today by Dr Tze-Fan Chao, cardiologist at Taipei Veterans General Hospital and the National Yang-Ming University in Taiwan.

Read more


Research Explores Impacts of CPR on Patient Outcomes

American College of Cardiology, 30 August 2015

New research presented on Aug. 30 during ESC Congress 2015 in London continues to prove that cardiopulmonary resuscitation (CPR) for out-of-hospital cardiac arrest can improve patient outcomes. However, there is still room for bystander education around CPR and use of automated external defibrillators (AEDs).

Read more


Wireless pacemaker gets cautious endorsement

CBS News, 30 August 2015

A tiny, wireless pacemaker could offer some heart patients a surgery-free alternative to the traditional devices, a new study says. Some doctors, however, say there are lingering safety questions and warned patients not to rush to get the new technology.

Read more


LEADLESS II: Safety and Efficacy of a Leadless Pacemaker

American College of Cardiology, 30 August 2015

The leadless cardiac pacemaker may be capable of providing effective pacemaker function in a varied group of patients needing long-term pacing therapy, according to results of the LEADLESS II Trial presented Aug. 30 at ESC Congress 2015 in London, and simultaneously published in the New England Journal of Medicine.

Read more


ESC: Leadless Pacemaker Results Promising at 6 Months

Med Page Today, 30 August 2015

Device effective in 90% of trial patients, but some concern over adverse event rate

Read more


 ESC recommends DNA analysis in post mortems of young sudden death victims

Eurek Alert, 29 August 2015

ESC Guidelines published today recommend DNA analysis as a fundamental component of post mortem assessment in young sudden death victims. Identification of a genetic cause helps to quickly diagnose and protect relatives.

Read more


Cell phones, electronic security systems, music players may affect cardiac devices

European Society of Cardiology, 29 August 2015

The role of environmental electromagnetic interference on pacemakers, ICDs and CRT devices will be under the environmental spotlight at a Symposium this afternoon when a session jointly organised with the Asian Pacific Society of Cardiology will consider the impact of mobile phones, security devices, portable headphones and other household devices.

Read more



BioControl Medical completes enrolment in the INOVATE-HF study of the CardioFit system to treat heart failure

Cardiac Rhythm News, 28 August 2015

BioControl Medical has completed enrolment in its INOVATE-HF (Increase of vagal tone in heart failure) clinical trial evaluating the CardioFit system for the treatment of congestive heart failure. INOVATE-HF has enrolled a total of 725 patients at 86 centres in the USA and Europe, making it the largest prospective, randomised device study to evaluate the treatment of heart failure with vagus nerve stimulation.

Read more


Postural modification to the standard Valsalva manoeuvre for emergency treatment of supraventricular tachycardias (REVERT): a randomised controlled trial

The Lancet, 27 August 2015
 

Summary
Background The Valsalva manoeuvre is an internationally recommended treatment for supraventricular tachycardia, but cardioversion is rare in practice (5–20%), necessitating the use of other treatments including adenosine, which patients often find unpleasant. We assessed whether a postural modification to the Valsalva manoeuvre could improve its effectiveness.

Read more


Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC Congress 2015

Business Wire, 26 August 2015
 

"The Bristol-Myers Squibb and Pfizer Alliance is pleased to share 22 abstracts, which include important Eliquis data from both clinical trials and real-world analyses, at one of the world’s largest and most influential cardiovascular meetings," said Douglas Manion, M.D., head of specialty development, Bristol-Myers Squibb.

Read more


HARMONY: Ranolazine, dronedarone combination benefits patients with paroxysmal AF

Healio Cardiology Today, 26 August 2015

Published data from the HARMONY trial confirm a previous report that moderate-dose ranolazine plus reduced-dose dronedarone was well-tolerated and reduced atrial fibrillation burden, according to a report in Circulation: Arrhythmia & Electrophysiology.

Read more


Lay Summary for research publication on emergency treatment for SVT (supraventricular tachycardias)

Revert, 25 August 2015
 

This lay summary is to inform study volunteers, patients and their carers of the outcome of this research and how the results may help them to better manage their condition.

Read more


Taxonomy of the burden of treatment: a multi-country web-based qualitative study of patients with chronic conditions
BMC Medicine, 30 July 2015

Management strategies for patients with chronic conditions are becoming increasingly complex,
which may result in a burden of treatment for patients.

Read more


A-Fib Drug Passes New Test

HCP Live, 27 July 2015

A new sub-analysis of data from the trial known as ROCKET-AF shows that rivaroxaban (Xarelto/Janssen) works as well in patients who have both non-valvular atrial fibrillation (AF) and diabetes as in similar AF patients without diabetes.

Read more
Accolade Pacing Systems

bostonscientificmail.eu, 12 May 2015
Discover the World’s First 3T MR-Conditional Pacemaker
Read more


Cardiac Rhythm News

www.cxvascular.com, 7 May 2015
Follow the link below to view 'Top stories', 'Features' and 'Industry News' from BIBA Medical Ltd
Read more


QiC Awards 2015

Quality in Care (QiC) Anticoagulation is an awards programme to recognise, reward and share good practice in anticoagulation management, education and patient care. The QiC Anticoagulation programme is comprised of a recognition event and subsequent dissemination opportunities for finalists to share good practice and demonstrate the benefits and adaptability of their initiatives to a wider healthcare audience. Gaining recognition through QiC Anticoagulation means an initiative has been highlighted by the NHS, patients and industry as improving patient outcomes and standards of care in the treatment and prevention of blood clots.
Visit website


Practices to provide warfarin clinics under CCG agreement

pulsetoday.co.uk, 9 April 2015
A CCG-GP ‘partnership’ agreement in Barnsley will fund GPs for visiting elderly or housebound patients at home to conduct medicines reviews and discuss end-of-life care, and increase the number of procedures that can be delivered by practices.
Read more


Meta-analysis: Oral anticoagulants superior to warfarin, closure device for stroke prevention

healio.com, 7 April 2015
A systematic review and meta-analysis of randomized controlled trials indicated treatment with novel oral anticoagulants was superior to warfarin and a left atrial appendage closure device for the prevention of stroke in patients with nonvalvular atrial fibrillation.
Read more


National Audit of Cardiac Ablation 2013-14

27 March 2015

The National Cardiac Rhythm Management Ablation Audit is managed by the National Institute for Cardiovascular Outcomes Research (NICOR), which is part of the National Centre for Cardiovascular Prevention and Outcomes, based at University College London. Specialist clinical knowledge and leadership is provided by the British Cardiovascular Society and British Heart Rhythm Society. The strategic direction and development of the audit is determined by the Audit Steering Group. This includes major stakeholders in the audit, including cardiologists, the professional societies, physiologists, commissioners and patient group representatives.

Download report

Read response from AF Association

ESC webinar on cardiac resynchronisation therapy: what do the ESC guidelines tell us?

ESC Education,